Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Completed · Not applicable

Conditions studied: Alopecia Areata, Alopecia Totalis, Alopecia Universalis

In brief

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Key facts

Study ID
NCT02312882
Run by
Stanford University
People needed
40
Starts
2014-12-01
Expected to finish
2015-08-01
Last updated by the study team
2017-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.